Hepatocellular carcinoma (HCC) is relatively common worldwide. Until a few years ago skeletal involvement from HCC was rarely diagnosed. Thanks to novel imaging techniques and multidisciplinary treatment approaches, the overall survival in HCC patients has prolonged, and bone involvement has significantly increased currently. This short review summaries the value of bone scintigraphy in patient...

Abstract Hepatocellular carcinoma (HCC) is a heterogeneous disease that often features dysregulated tumour lipid metabolism. ACSL3 and ACSL4 are two homologous long chain acyl‐coenzyme A synthetases (ACSL) preferentially catalyse the activation of monounsaturated polyunsaturated fatty acids, respectively. Both enzymes frequently overexpressed in HCC, multiple reports have implicated progression...

Purpose: MET signaling has been suggested a potential role in hepatocellular carcinoma (HCC) and associated with prometastasis during antiangiogenesis therapy. We investigated the potential association between MET expression and therapeutic response to sorafenib in patients with HCC. Antitumor effects of cabozantinib, a dual inhibitor of MET and VEGFR2, were examined in cultured HCC cells as we...

Natural killer (NK) cells are potential immune components against hepatocellular carcinoma (HCC) after curative hepatectomy. Patients at high risk of HCC recurrence can be identified by quantifying NK cell licensing. Therefore, therapeutic strategies that manipulate NK cell activity may possibly improve the prognosis of HCC patients.

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death and is the most common type of liver cancer. Current therapies for hepatocellular carcinoma are still rather limited and novel therapeutic strategies are required. Baicalein, extracted from Scutellaria baicalensis, has anticancer effects on HCC in vitro and vivo. However, the detailed mechanisms are not well studied yet. ...

hepatocellular carcinoma (hcc) is the fifth most common tumor in the world, and its incidence is increasing. it is second most common cause of cancer related death worldwide and fastest growing cause of cancer death in the united states. cirrhosis is the most important clinical risk factor for hcc, with approximately 80% of cases of hcc developing in patients with a cirrhotic liver. hcc differs...

Oncological diseases are one of the leading health problems both in world and Kazakhstan, second only to cardiovascular diseases. Hepatocellular carcinoma occupies 8th place structure oncopathologies, has an unfavorable prognosis course. According WHO, more than 1.3 million people die each year from hepatocellular (HCC). The incidence rate HCC Kazakhstan is up 5.5 cases per 100 thousand populat...

Abstract Understanding the mechanisms underlying evasive resistance in cancer is an unmet medical need to improve efficacy of current therapies. In hepatocellular carcinoma (HCC), aberrant expression hypoxia-inducible factor 1 α (HIF1α) and increased aerobic glycolysis metabolism are drivers therapy with multi-kinase inhibitor Sorafenib. However, it has remained unknown how HIF1α activated its ...

Background: Hepatocellular carcinoma (HCC), primary liver cancer, is a major health problem and the third most common cause of cancer-related deaths worldwide. Epigenetic modulations are essential for the maintenance of gene expression patterns in mammals. Disruption of these processes can lead to silenced gene and malignant cellular transformation. The current study was designed to compare the...

OBJECTIVE To evaluate the diagnostic utility of Hep par-1 in differentiating hepatocellular carcinoma from metastatic carcinoma taking histopathology as a gold standard. STUDY DESIGN Comparative cross-sectional study. PLACE AND DURATION OF STUDY Pathology Department, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, from April 2007 to February 2008. METHODOLOGY Hep par-...